CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial.

ABSTRACT:

Background

A substantial proportion of breast cancer patients develop metastatic disease, with over 450,000 deaths globally per year. Bone is the most common first site of metastatic disease accounting for 40% of all first recurrence and 70% of patients with advanced disease develop skeletal involvement. Treatment of bone metastases currently focusses on symptom relief and prevention and treatment of skeletal complications. However, there remains a need for further treatment options for patients with bone metastases. Combining systemic therapy with a bone-targeted agent, such as radium-223, may provide an effective treatment with minimal additional side effects.

Methods/design

CARBON is a UK-based, open-label, multi-centre study which comprises an initial safety phase to est

SUBMITTER: Coleman R 

PROVIDER: S-EPMC6961242 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature